Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Clinical trial NCT06669572 · RECRUITING
Trial details
- NCT number
- NCT06669572
- Sponsor
- University of Chicago
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-11
- Primary completion
- 2029-03-26
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.